Our technology

Our technology is a highly specific and modular platform that enables us to inhibit or ‘silence’ the expression of disease-causing genes, allowing cells to revert to their healthy state. We achieve this through harnessing the endogenous pathway of RNA interference (RNAi), which was a breakthrough discovery in the field of molecular biology that was first described in the late 1990s and later recognised with a Nobel prize in 2006.

Given the tailored inhibition of selected genes and the added precision brought by targeted delivery systems, RNAi-based therapies are thought to carry lower risk of failure than traditional approaches as the biological effects are more predictable. We are working to maximise the therapeutic applications of our versatile toolkit.


Intellectual Property

Our intellectual property (IP) portfolio reflects the innovative work that we have carried out in the field of RNAi. Our IP captures chemical modifications that are necessary for the delivery of stable siRNA molecules, siRNA structures and particularly potent sequences, as well as effective delivery methods.

  • Specific siRNA molecules
  • Stabilisation technology
  • Exclusive structural features
  • Delivery systems

RNA Interference

We design short interfering RNA (siRNA) molecules that are able to trigger the RNAi pathway and mediate the degradation of specific target messenger RNAs (mRNAs), resulting in the expression of a particular disease-causing gene being inhibited.

Our therapeutic siRNA molecules are combined with delivery systems, which markedly enhance the efficiency and specificity of our siRNA drugs by directing them to the right cell type in the body and sparing healthy tissues.



Partnerships & Collaborations


At Silence we are developing novel RNAi based therapies with the potential to transform patients’ lives. We use our proprietary technology platform to advance the next generation of genetic medicines, designed to intervene at the root of the problem by targeting the expression of disease-causing genes. 

We envisage partnerships with pharmaceutical and biotech companies, as well as leading academic institutions, as an essential component of our product development strategy. We are committed to creating collaborations that maximise value for each of the partners.